Skip to main content
. 2007 May 7;51(7):2470–2482. doi: 10.1128/AAC.00069-07

TABLE 3.

Partial protection against WNV disease in mice treated with conjugated PPMOsa

Inoculum Antiviral treatment
Disease outcome
Treatment Dose (μg) Treatment days Morbidity (no. of sick mice/total no. in group) Mortality (no. of mice that died/total no. in group) Avg day of disease onset (SD)b Avg survival time (SD)c
Diluent Vehicle NA 0 to 8 0/4 0/4 NA NA
WNV 5′-end PPMO 200 0 to 8 5/8* 3/8 9.8 (1.48)*** 17.3 (5.13)***
5′-end PPMO 100 0 to 8 8/8 5/8 9.1 (1.55)** 11.4 (3.71)
3′ CSI PPMO 200 0 to 8 8/8 4/8 10.8 (2.92)** 13.0 (3.46)*
3′ CSI PPMO 100 0 to 8 8/8 3/8 11.3 (2.49)*** 11.3 (0.58)
Scramble PPMO 200 0 to 8 8/8 6/8 7.6 (0.92) 9.7 (0.46)
Scramble PPMO 100 0 to 8 8/8 6/8 7.6 (0.52) 11.0 (2.00)
Vehicle NA 0 to 8 8/8 7/8 8.1 (1.55) 10.43 (2.3)
Diluent Vehicle NA 5 to 15 0/4 0/4 NA NA
WNV 5′-end PPMO 200 5 to 15 8/8 4/8 7.6 (0.74) 11.0 (4.08)
Scramble PPMO 200 5 to 15 8/8 6/8 7.4 (0.52) 9.8 (2.32)
Vehicle NA 5 to 15 8/8 7/8 7.5 (0.53) 9.3 (1.50)
a

Six-week-old C3H female mice were inoculated s.c. in the left rear footpad with 103 PFU of WNV or diluent alone on day 0. The mice were then inoculated i.p. daily on days 0 to 8 or days 5 to 15 with the indicated treatments. Mice were monitored for weight loss and clinical signs. Surviving mice were bled on days 35 to 37 postinoculation and tested for WNV-specific antibody by enzyme-linked immunosorbent assay; all WNV-inoculated mice were seropositive, and mock-inoculated mice were seronegative. NA, not applicable. Levels of statistical significance in comparisons of results for the indicated group to those for the group receiving the scramble conjugate at the same dose are noted as follows: *, P ≤ 0.05; **, P ≤ 0.01; ***, P ≤ 0.005.

b

Average day of disease onset postinoculation for mice that became sick only.

c

Average survival time in days for mice that died.